These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32445965)

  • 1. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal nanoparticles for retinal delivery.
    Huang X; Chau Y
    Drug Discov Today; 2019 Aug; 24(8):1510-1523. PubMed ID: 31102730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].
    Jonas JB; Kreissig I; Kamppeter B; Degenring RF
    Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
    Li J; Lan B; Li X; Sun S; Lu P; Cheng L
    J Control Release; 2016 Dec; 243():78-85. PubMed ID: 27717742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases.
    Shatz W; Aaronson J; Yohe S; Kelley RF; Kalia YN
    Expert Opin Drug Deliv; 2019 Jan; 16(1):43-57. PubMed ID: 30488721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development.
    Awwad S; Lockwood A; Brocchini S; Khaw PT
    J Pharm Sci; 2015 Oct; 104(10):3330-42. PubMed ID: 26108574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.
    Ma F; Nan K; Lee S; Beadle JR; Hou H; Freeman WR; Hostetler KY; Cheng L
    Eur J Pharm Biopharm; 2015 Jan; 89():271-9. PubMed ID: 25513956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.
    Quiroz-Mercado H; Ustariz-González O; Martinez-Castellanos MA; Covarrubias P; Dominguez F; Sanchez-Huerta V
    Semin Ophthalmol; 2007; 22(2):109-25. PubMed ID: 17564934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2nd Ophthalmic Drug Development and Delivery Summit.
    Marra M; Gukasyan HJ; Raghava S; Kompella UB
    Expert Opin Drug Deliv; 2007 Jan; 4(1):77-85. PubMed ID: 17184164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease.
    Campbell M; Doyle SL
    Biochem Pharmacol; 2019 Jun; 164():321-325. PubMed ID: 31039332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.
    Ahn SJ; Hong HK; Na YM; Park SJ; Ahn J; Oh J; Chung JY; Park KH; Woo SJ
    J Vis Exp; 2016 Jul; (113):. PubMed ID: 27500363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
    Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
    Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.
    Zhang Y; Bazzazi H; Lima E Silva R; Pandey NB; Green JJ; Campochiaro PA; Popel AS
    Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):5266-5276. PubMed ID: 30383198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics.
    Laude A; Tan LE; Wilson CG; Lascaratos G; Elashry M; Aslam T; Patton N; Dhillon B
    Prog Retin Eye Res; 2010 Nov; 29(6):466-75. PubMed ID: 20452456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits.
    Alshaikh RA; Salah El Din RA; Zaki RGE; Waeber C; Ryan KB
    Mol Pharm; 2024 Jul; 21(7):3310-3320. PubMed ID: 38856116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.